Public Policy Engagement
Public policy engagement is an important and appropriate role for private sector companies. At Celgene, we believe it is essential to work with public policymakers to help ensure that the policy environment is supportive of patient access to life-changing medications and enhances the promise of medical innovation. Our public policy advocacy reflects our commitment to improving the lives of patients and advancing the course of human health through innovation and bold pursuits of science.
Government policies directly impact healthcare access and innovation. These policies affect many aspects of Celgene’s business model, including our ability to meet patient needs and provide value to all our stakeholders. For these reasons, we actively participate in public policy discussions to share our perspectives and experience as an innovative biopharmaceutical company committed to advancing therapies for patients with unmet medical needs. Celgene’s public policy priorities and positions are determined in consultation with the company’s business operations and approved by our senior management. A summary of Celgene’s public policy priorities from our most recent Corporate Responsibility report is available here
Celgene has a Corporate Policy on Political Contributions and Lobbying that governs the company’s lobbying and political activities. The Policy governs both direct lobbying (requiring that any direct lobbying on behalf of Celgene be approved in advance and conducted in accordance with U.S. federal and state law) and grassroots lobbying (communicating with the public or a segment of the public encouraging contact with public officials on public policy issues).
Celgene complies with all U.S. federal and state laws regulating lobbying activities, including reporting and disclosure requirements. We file quarterly reports of our federal lobbying activity and biannual contribution reports in accordance with the Honest Leadership and Open Government Act of 2007. These reports are publicly available here.
Celgene is registered with the European Union Transparency Register established by the European Parliament and European Commission and supported by the Council of the European Union. This voluntary register and associated code of conduct provides citizens direct access to information about who is engaged in activities aimed at influencing the EU decision making process, which interests are being pursued and what level of resources are invested in these activities. Click here for Celgene’s registration.
Celgene is a member of a number of associations that represent the biopharmaceutical sector and the business community in general. These organizations serve a variety of purposes such as speaking with a uniform voice with policymakers on public policy issues or collaborating on education and advocacy activities. Our participation in these associations is grounded in the understanding that we may not always agree with all of the positions taken by the association or its other members. Celgene representatives serve on various boards and committees within these organizations to share Celgene’s perspective on the issues and advocate for policies that advance patient access and innovation in health care.
Click here for a listing of Celgene’s association memberships around the world.
Celgene also participates with tax-exempt state legislative membership organizations that write and endorse model legislation, including providing support in 2017 to the Council of State Governments ($11,000.00) and the American Legislative Exchange Council ($30,500.00).
With respect to political activity in the U.S., Celgene’s Corporate Policy on Political Contributions and Lobbying prohibits use of corporate resources on political activity except with respect to the Celgene Corporation Political Action Committee (Celgene PAC) and corporate political contributions in states where permitted by law.
The Celgene PAC is a voluntary organization funded by contributions from eligible employees. It is governed by the Celgene PAC Board, consisting of a cross-functional group of company employees that makes decisions on any political contributions made by the Celgene PAC or by the company. These contributions are reported to the Federal Election Commission on a regular basis, available here , and to state election commissions as required by law. In addition, to ensure transparency, information about all political contributions in the U.S. by the Celgene PAC or the company is provided in a semiannual report posted on the company website, categorized by state, candidate, political affiliation and amount.
Click here for more information on Celgene PAC and Political Contributions Governance and Transparency.
Click here for the Second Half 2017 Political Contributions Report, including all political contributions by Celgene PAC and the Company made in the U.S. in the second half of 2017.
Previous Political Contributions Reports
- Read the First Half of 2017 Political Contributions Report
- Read the Second Half 2016 Political Contributions Report
- Read the First Half 2016 Political Contributions Report
- Read the Second Half 2015 Political Contributions Report
- Read the First Half 2015 Political Contributions Report
- Read the Second Half 2014 Political Contributions Report
- Read the First Half 2014 Political Contributions Report
- Read the Second Half 2013 Political Contributions Report
- Read the First Half 2013 Political Contributions Report
- Read the 2012 Political Contributions Report
Celgene’s Executive Vice President of Corporate Affairs and Market Access, who reports to the Chairman and Chief Executive Officer and serves on Celgene’s Executive Committee, is responsible for Celgene’s public policy, advocacy and political activity (including Celgene PAC, corporate political contributions and ensuring compliance with the Corporate Policy on Political Contributions and Lobbying), and provides periodic updates to the Executive Committee on these initiatives. In addition, at least annually, a report on public policy advocacy and political activity is provided to the Nominating, Governance and Compliance Committee of the Board of Directors.